Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis

Background: The clinical-stage drug candidate EBL-1003 (apramycin) represents a distinct new subclass of aminoglycoside antibiotics for the treatment of drug-resistant infections. It has demonstrated best-in-class coverage of resistant isolates, and preclinical efficacy in lung infection models. How...

Full description

Saved in:
Bibliographic Details
Main Authors: Katja Becker, Sha Cao, Anna Nilsson, Maria Erlandsson, Sven-Kevin Hotop, Janis Kuka, Jon Hansen, Klara Haldimann, Solveiga Grinberga, Talia Berruga-Fernández, Douglas L. Huseby, Reza Shariatgorji, Evelina Lindmark, Björn Platzack, Erik C. Böttger, David Crich, Lena E. Friberg, Carina Vingsbo Lundberg, Diarmaid Hughes, Mark Brönstrup, Per E. Andrén, Edgars Liepinsh, Sven N. Hobbie
Format: article
Language:EN
Published: Elsevier 2021
Subjects:
R
Online Access:https://doaj.org/article/b25c8a267d4642389bf6d5a2908a5a98
Tags: Add Tag
No Tags, Be the first to tag this record!